Sex differences in CYP3A activity using intravenous and oral midazolam

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 531-538

  Chen, Maylee ^a   Ma, Lei ^a   Drusano, George L ^a   Bertino Jr , Joseph S ^a   Nafziger, Anne N ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; BAYES THEOREM; BODY WEIGHT; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; ENZYME ACTIVITY; EUROPEAN AMERICAN; FEMALE; GENE ACTIVITY; HUMAN; HUMAN EXPERIMENT; INTESTINE; LIVER; MALE; MONTE CARLO METHOD; NONPARAMETRIC TEST; NORMAL HUMAN; POPULATION MODEL; PRIORITY JOURNAL; PROBABILITY; RACE DIFFERENCE; SEX DIFFERENCE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BAYES THEOREM; CLINICAL TRIALS; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MONTE CARLO METHOD; SEX FACTORS;

EID: 33750946415     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.014     Document Type: Article

References (42)

1. Yee G.C., Lennon T.P., Gmur D.J., Kennedy M.S., and Deeg H.J. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40 (1986) 438-443
2. Lew K.H., Ludwig E.A., Milad M.A., Donovan K., Middleton Jr. E., Ferry J.J., et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54 (1993) 402-414
3. Greenblatt D.J., Allen M.D., Harmatz J.S., and Shader R.I. Diazepam disposition determinants. Clin Pharmacol Ther 27 (1980) 301-312
4. Schroeder T.J., Cho M.J., Pollack G.M., Floc'h R., Moran H.B., Levy R., et al. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. J Clin Pharmacol 38 (1998) 807-814
5. Greenblatt D.J., Harmatz J.S., von Moltke L.L., Wright C.E., and Shader R.I. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 76 (2004) 467-479
6. Krecic-Shepard M.E., Barnas C.R., Slimko J., and Schwartz J.B. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 68 (2000) 286-292
7. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
8. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., and Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80 (1987) 1029-1036
9. Wolbold R., Klein K., Burk O., Nussler A.K., Neuhaus P., Eichelbaum M., et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38 (2003) 978-988
10. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
11. Streetman D.S., Bleakley J.F., Kim J.S., Nafziger A.N., Leeder J.S., Gaedigk A., et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail.". Clin Pharmacol Ther 68 (2000) 375-383
12. Kashuba A.D., Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R., Rocci Jr. M.L., et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 64 (1998) 257-268
13. Rogers J.F., Morrison A.L., Nafziger A.N., Jones C.L., Rocci Jr. M.L., and Bertino Jr. J.S. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther 72 (2002) 711-717
14. Shelepova T., Nafziger A.N., Victory J., Kashuba A.D., Rowland E., Zhang Y., et al. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45 (2005) 1413-1421
15. Lowry J.A., Kearns G.L., Abdel-Rahman S.M., Nafziger A.N., Khan I.S., Kashuba A.D., et al. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther 73 (2003) 209-222
16. Chung E., Nafziger A.N., Kazierad D.J., and Bertino Jr. J.S. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79 (2006) 350-361
17. Ma J.D., Nafziger A.N., Rhodes G., Liu S., Gartung A.M., and Bertino Jr. J.S. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 46 (2006) 103-108
18. Ma J.D., Nafziger A.N., Rhodes G., Liu S., and Bertino Jr. J.S. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 34 (2006) 783-785
19. Ma J.D., Nafziger A.N., Villano S.A., Gaedigk A., and Bertino Jr. J.S. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 50 (2006) 1130-1135
20. Johnson B.M., Song I.H., Adkison K.K., Borland J., Fang L., Lou Y., et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail. J Clin Pharmacol 46 (2006) 577-587
21. Ma J.D., Nafziger A.N., Mylott W., Haughey D.B., Rocci Jr. M.L., and Bertino Jr. J.S. Effects of posture induced changes in hepatic blood flow (HBF) and plasma protein binding (PB) on the clearance (CL) of the intravenous (IV) cytochrome P450 3A (CYP3A) biomarker midazolam (MDZ). [abstract]. Clin Pharmacol Ther 77 (2005) P33
22. Lawendy N., Holt J.L., Fullerton T., Nafziger A.N., Snyder P.J., Victory J., et al. Pharmacokinetics and pharmacodynamics of orally administered midazolam in the presence and absence of intravenous flumazenil in healthy volunteers [abstract]. Clin Pharmacol Ther 73 (2003) P15
23. Lee LS, Nafziger AN, Michalak C, Bertino JS. Jr. Effect of azithromycin, levofloxacin and telithromycin on the activities of cytochrome P450 1A2, 2C9, 2C19, 2D6, 3A, N-acetyltransferase-2 (NAT-2) and xanthine oxidase (XO) as assessed by the Cooperstown 5+1 cocktail [abstract]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 17, 2005; Washington, DC.
24. Kashuba A.D., Bertino Jr. J.S., Rocci Jr. M.L., Kulawy R.W., Beck D.J., and Nafziger A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 64 (1998) 269-277
25. Leary R., Jelliffe R., Schumitzky A., and Van Guilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models (2001), IEEE Computer Society, Bethesda 389-394 In: Proceedings of the 14th IEEE Symposium on Computer Based Medical Systems.
26. Tsunoda S.M., Velez R.L., von Moltke L.L., and Greenblatt D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66 (1999) 461-471
27. Greenblatt D.J., Abernethy D.R., Locniskar A., Harmatz J.S., Limjuco R.A., and Shader R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61 (1984) 27-35
28. He P., Court M.H., Greenblatt D.J., and Von Moltke L.L. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77 (2005) 373-387
29. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59 (1996) 491-502
30. Bjornsson T.D., Wagner J.A., Donahue S.R., Harper D., Karim A., Khouri M.S., et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 43 (2003) 943-967
31. Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24 (1996) 475-490
32. Floyd M.D., Gervasini G., Masica A.L., Mayo G., George Jr. A.L., Bhat K., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13 (2003) 595-606
33. Hunt C.M., Westerkam W.R., and Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44 (1992) 275-283
34. Schmucker D.L., Woodhouse K.W., Wang R.K., Wynne H., James O.F., McManus M., et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48 (1990) 365-374
35. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
36. George J., Byth K., and Farrell G.C. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50 (1995) 727-730
37. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
38. Wilkinson G.R. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin Pharmacol Ther 76 (2004) 99-103
39. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30 (2002) 883-891
40. Yu A.M., Fukamachi K., Krausz K.W., Cheung C., and Gonzalez F.J. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 146 (2005) 2911-2919
41. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16 (1999) 408-414
42. Tolle-Sander S., Rautio J., Wring S., Polli J.W., and Polli J.E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20 (2003) 757-764